OPGENOperational General
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
OpGen said that the merger provides it with a family of FDA approved and CE marked rapid molecular tests for use with the company's Acuitas MDRO Gene tests and bioinformatics for multi-drug resistant organisms.
Lifescience company Fluidigm (NasdaqGS:FLDM) said on Monday that it has expanded its agreement for the development of test kits and custom analytic instruments for identification, screening, and surveillance testing of multi-drug resistance organism (MDRO) genes of pathogens, including bacteria, fungi and viruses, in collaboration with OpGen (NasdaqCM:OPGN).
How have OpGen's solutions evolved in recent years to address changing customer needs?
Molecular testing company OpGen (NasdaqCM:OPGN) said on Tuesday that it has agreed to acquire AdvanDx in a merger combination.
Bioinformatics company OpGen (NasdaqCM:OPGN) stated on Wednesday its net loss attributed to common stockholders of USD2.8m (USD5.61 per share) for the three months ended 31 March 2015.
Circular, highresolution NcoI restriction maps of the ON-2010 ([approximately equal to] 5.1 Mbp) and ON-2011 (-5.25 Mbp) genomes were generated by optical mapping (Argus Optical Mapper, OpGen, Inc, Gaithersburg, MD, USA).
OpGen announced that data from its Acuitas AMR Gene Panel and Acuitas Lighthouse Software will be presented at ASM Microbe 2019 being held June 20-24 in San Francisco, California at the Moscone Convention Center.
M2 EQUITYBITES-July 14, 2015-Fluidigm partners with OpGen for development of test kits and custom analytic instruments for multi-drug resistance organism genes of pathogens
16 May 2014 - US genetic analysis company OpGen Inc said yesterday it had introduced the Acuitas MDRO Gene Test, a molecular screening tool able to rapidly detect patients at risk for harbouring serious antibiotic resistant disease-causing microbes.
Carroll, MD, has disclosed the following relevant relationships: served as an advisor or consultant for Quidel Diagnostics; OpGen, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; received grants for clinical research from BD GeneOhm; Ibis Biosciences, Inc.; MicroPhage, Inc.
OpGen, Inc.(NASDAQ: OPGN) shares shot up 64% to $10.70 after the company announced it will acquire Curetis.